Merck & Co., Inc. / Afferent Pharmaceuticals, Inc.

Refractory chronic cough and idiopathic pulmonary fibrosis (IPF) cough

Disease Overview

Refractory chronic cough is a cough lasting more than eight weeks that persists despite optimal treatment of underlying conditions (asthma, GERD, postnasal drip), affecting an estimated 12 million US adults with chronic cough overall and a meaningful subset categorized as refractory or unexplained. The condition imposes significant psychosocial burden including sleep disruption, depression, and stress urinary incontinence, with no FDA-approved targeted therapy at the time of the 2016 Merck-Afferent deal. P2X3 receptors on vagal sensory afferents drive the hypersensitive cough reflex, providing a mechanistic target.

Competitive Landscape

At deal close (June 2016), refractory chronic cough was a category-creating greenfield with no FDA-approved targeted therapies. Standard-of-care fell back to off-label opioids (codeine), gabapentinoids, neuromodulators (amitriptyline), and speech therapy, all with limited efficacy and significant tolerability issues. AF-219 (later gefapixant / MK-7264) was the most clinically advanced P2X3 antagonist in development, giving Merck a potential first-in-class position in a multi-billion-dollar greenfield. Competitors emerged in parallel: Bayer's eliapixant (P2X3, discontinued February 2022 due to taste-related adverse events), Bellus Health's camlipixant (BLU-5937, more selective P2X3 with lower taste signal), and Shionogi's sivopixant. The thesis partially unraveled when the FDA issued Complete Response Letters for gefapixant in January 2022 (effectiveness questions and dysgeusia tolerability concerns) and again in December 2023 after FDA advisors voted against approval. Gefapixant was approved in Japan as Lyfnua. GSK subsequently acquired Bellus for $2B in 2023 to gain camlipixant, validating the underlying P2X3 thesis even as Merck's specific molecule struggled.